ATRX (RBT-ATRX), RMab

Summary and Explanation

Mutation/loss of ATRX antibody expression has been described in anaplastic gliomas. A study explored the role of ATRX status in the molecular classification of anaplastic gliomas and its impact on survival. Loss of ATRX antibody expression was detected in 45 % of anaplastic astrocytomas (AA), 27 % of anaplastic oligoastrocytomas (AOA) and 10 % of anaplastic oligodendrogliomas (AO). Survival analysis showed a marked separation of IDH mutant astrocytic tumors into two groups based on ATRX status: tumors with ATRX loss had a significantly better prognosis. Another recent study analyzed the use of ATRX, IDH and 1p/19q codeletion in a series of astrocytomas, oligodendrogliomas, oligoastrocytomas and glioblastomas and presented an algorithm based on stepwise analysis with initial immunohistochemistry for ATRX and IDH1-R132H followed by 1p/19q analysis, then by IDH sequencing, which reduces the number of molecular analyses and has a far better association with patient outcome.

---

Synonyms: atrx, anti-atrx, α-thalassemia mental retardation syndrome X-linked